Chee-Ruey Hsieh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10388146/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The prevalence of depression and depressive symptoms among adults in China: Estimation based on a National Household Survey. China Economic Review, 2018, 51, 271-282.	4.4	132
2	Financial incentives and physicians' prescription decisions on the choice between brand-name and generic drugs: Evidence from Taiwan. Journal of Health Economics, 2009, 28, 341-349.	2.7	95
3	Depression hurts, depression costs: The medical spending attributable to depression and depressive symptoms in China. Health Economics (United Kingdom), 2018, 27, 525-544.	1.7	90
4	Health Information and the Demand for Preventive Care among the Elderly in Taiwan. Journal of Human Resources, 1997, 32, 308.	3.1	69
5	Smoking, health knowledge, and anti-smoking campaigns: An empirical study in Taiwan. Journal of Health Economics, 1996, 15, 87-104.	2.7	62
6	Economic growth and the geographic maldistribution of health care resources: Evidence from China, 1949-2010. China Economic Review, 2014, 31, 228-246.	4.4	47
7	Records of medical malpractice litigation: a potential indicator of health-care quality in China. Bulletin of the World Health Organization, 2017, 95, 430-436.	3.3	37
8	Too few doctors or too low wages? Labor supply of health care professionals in China. China Economic Review, 2013, 24, 150-164.	4.4	35
9	Health risk and the decision to quit smoking. Applied Economics, 1998, 30, 795-804.	2.2	30
10	THE DEMAND FOR CIGARETTES IN TAIWAN: DOMESTIC VERSUS IMPORTED CIGARETTES. Contemporary Economic Policy, 1999, 17, 223-234.	1.7	28
11	Cost of Chronic Hepatitis B Virus Infection in Taiwan. Journal of Clinical Gastroenterology, 2004, 38, S148-S152.	2.2	25
12	The multi-tiered medical education system and its influence on the health care market—China's Flexner Report. Human Resources for Health, 2019, 17, 50.	3.1	24
13	Adoption of Pharmaceutical Innovation and the Growth of Drug Expenditure in Taiwan: Is It Cost Effective?. Value in Health, 2008, 11, 334-344.	0.3	19
14	Regulation and competition in the Taiwanese pharmaceutical market under national health insurance. Journal of Health Economics, 2012, 31, 471-483.	2.7	19
15	The determinants of the adoption of pharmaceutical innovation: Evidence from Taiwan. Social Science and Medicine, 2011, 72, 919-927.	3.8	18
16	Understanding and Addressing the Treatment Gap in Mental Healthcare: Economic Perspectives and Evidence From China. Inquiry (United States), 2020, 57, 004695802095056.	0.9	13
17	New drugs and the growth of health expenditure: evidence from diabetic patients in Taiwan. Health Economics (United Kingdom), 2012, 21, 496-513.	1.7	10
18	Biopharmaceutical innovation and industrial developments in South Korea, Singapore and Taiwan. Australian Health Review, 2009, 33, 245.	1.1	9

CHEE-RUEY HSIEH

#	Article	IF	CITATIONS
19	The Hidden Costs of Mental Depression: Implications on Social Trust and Life Satisfaction. Manchester School, 2019, 87, 259-296.	0.9	7
20	Availability, Health-Care Costs, and Utilization Patterns of Biologics in Taiwan. Value in Health, 2012, 15, S35-S42.	0.3	6
21	Are smokers too optimistic about their health status: Ex ante perception versus ex post observation. China Economic Review, 2017, 43, 169-183.	4.4	3
22	Endogenous technological change in medicine and its impact on healthcare costs: evidence from the pharmaceutical market in Taiwan. European Journal of Health Economics, 2013, 14, 287-295.	2.8	2
23	Profit-Seeking Behavior of Medical Providers and Generic Competition in the Pharmaceutical Market: Evidence from Taiwan. B E Journal of Economic Analysis and Policy, 2014, 14, 241-275.	0.9	1
24	Pharmaceuticals, Health Policy and Intellectual Property Rights in China. , 2013, , 48-69.		1
25	Agency Problem and Health Care Expenditure: Evidence from Terminally-III Patients in Taiwan. SSRN Electronic Journal, 0, , .	0.4	0